Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 2/2008

01.12.2008 | Short Report

Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX

verfasst von: M. G. M. de Sain-van der Velden, A. Verrips, B. H. C. M. T. Prinsen, M. de Barse, R. Berger, G. Visser

Erschienen in: Journal of Inherited Metabolic Disease | Sonderheft 2/2008

Einloggen, um Zugang zu erhalten

Summary

Cerebrotendinous xanthomatosis (CTX) is an inborn error of bile acid synthesis in which hepatic conversion of cholesterol to cholic and chenodeoxycholic acids is impaired. Patients have abnormal bile alcohols in urine, normal to increased plasma cholesterol concentrations and increased concentrations of plasma cholestanol. Little is known about cholesterol precursors in CTX, however. We studied cholesterol and phytosterol profiles in two siblings with CTX during follow-up. While cholesterol concentrations were low in both patients, plasma cholestanol was 6-fold higher compared to control values. In addition, both siblings had a more than 100-fold increase in 7-dehydrocholesterol (7DHC) and 8-dehydrocholesterol (8DHC). Lathosterol, lanosterol and sitosterol were increased in both patients while concentrations of desmosterol and campesterol were normal. In addition, plasma lathosterol/cholesterol ratios were significantly elevated. After treatment with chenodeoxycholate, both patients showed a marked decrease in cholestanol, 7DHC, 8DHC, lathosterol, lanosterol and sitosterol. In addition, the lathosterol/cholesterol ratio normalized, indicating that overall cholesterol synthesis was sufficiently suppressed. This study shows that elevated cholesterol precursors, other than cholestanol, can be a hallmark for CTX.
Literatur
Zurück zum Zitat Batta AK, Shefer S, Batta M, et al (1985) Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. J Lipid Res 26: 690–698.PubMed Batta AK, Shefer S, Batta M, et al (1985) Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. J Lipid Res 26: 690–698.PubMed
Zurück zum Zitat Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311: 1649–1652.PubMedCrossRef Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311: 1649–1652.PubMedCrossRef
Zurück zum Zitat Cali JJ, Hsieh CL, Francke U, et al (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266: 7779–7783.PubMed Cali JJ, Hsieh CL, Francke U, et al (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266: 7779–7783.PubMed
Zurück zum Zitat Carlson TL, Kottke BA (1989) Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells. Biochem J 264: 241–247.PubMed Carlson TL, Kottke BA (1989) Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells. Biochem J 264: 241–247.PubMed
Zurück zum Zitat Hoshita T, Yasuhara M, Une M, et al (1980) Occurrence of bile alcohol glucuronides in bile of patients with cerebrotendinous xanthomatosis. J Lipid Res 21: 1015–1021.PubMed Hoshita T, Yasuhara M, Une M, et al (1980) Occurrence of bile alcohol glucuronides in bile of patients with cerebrotendinous xanthomatosis. J Lipid Res 21: 1015–1021.PubMed
Zurück zum Zitat Kuriyama M, Fujiyama J, Kasama T, et al (1991) High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis. J Lipid Res 32: 223–229.PubMed Kuriyama M, Fujiyama J, Kasama T, et al (1991) High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis. J Lipid Res 32: 223–229.PubMed
Zurück zum Zitat Lee MH, Hazard S, Carpten JD, et al (2001) Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res 42: 159–169.PubMed Lee MH, Hazard S, Carpten JD, et al (2001) Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res 42: 159–169.PubMed
Zurück zum Zitat Meiner V, Meiner Z, Reshef A, et al (1994) Cerebrotendinous xanthomatosis: molecular diagnosis enables presymptomatic detection of a treatable disease. Neurology 44: 288–290.PubMed Meiner V, Meiner Z, Reshef A, et al (1994) Cerebrotendinous xanthomatosis: molecular diagnosis enables presymptomatic detection of a treatable disease. Neurology 44: 288–290.PubMed
Zurück zum Zitat Menkes JH, Schimschock JR, Swanson PD, et al (1968) Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol 19: 47–53.PubMed Menkes JH, Schimschock JR, Swanson PD, et al (1968) Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol 19: 47–53.PubMed
Zurück zum Zitat Nakamura T, Matsuzawa Y, Takemura K, et al (1991) Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 40: 741–746. doi:10.1016/0026-0495(91)90094-D.PubMedCrossRef Nakamura T, Matsuzawa Y, Takemura K, et al (1991) Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 40: 741–746. doi:10.​1016/​0026-0495(91)90094-D.PubMedCrossRef
Zurück zum Zitat Nicolau G, Shefer S, Salen G, et al (1974) Determination of hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in man. J Lipid Res 15: 94–98.PubMed Nicolau G, Shefer S, Salen G, et al (1974) Determination of hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in man. J Lipid Res 15: 94–98.PubMed
Zurück zum Zitat Salen G, Shefer S, Setoguchi T, et al (1975) Bile alcohol metabolism in man. Conversion of 5beta-cholestane-3alpha, 7alpha,12alpha, 25-tetrol to cholic acid. J Clin Invest 56: 226–231. doi:10.1172/JCI108071.PubMedCrossRef Salen G, Shefer S, Setoguchi T, et al (1975) Bile alcohol metabolism in man. Conversion of 5beta-cholestane-3alpha, 7alpha,12alpha, 25-tetrol to cholic acid. J Clin Invest 56: 226–231. doi:10.​1172/​JCI108071.PubMedCrossRef
Zurück zum Zitat Salen G, Shefer S, Tint GS, et al (1985) Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. J Clin Invest 76: 744–751. doi:10.1172/JCI112030.PubMedCrossRef Salen G, Shefer S, Tint GS, et al (1985) Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. J Clin Invest 76: 744–751. doi:10.​1172/​JCI112030.PubMedCrossRef
Zurück zum Zitat Salen G, Batta AK, Tint GS, et al (1994) Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Metabolism 43: 1018–1022. doi:10.1016/0026-0495(94)90183-X.PubMedCrossRef Salen G, Batta AK, Tint GS, et al (1994) Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Metabolism 43: 1018–1022. doi:10.​1016/​0026-0495(94)90183-X.PubMedCrossRef
Zurück zum Zitat Segev H, Reshef A, Clavey V, et al (1995) Premature termination codon at the sterol 27-hydroxylase gene causes cerebrotendinous xanthomatosis in a French family. Hum Genet 95: 238–240. doi:10.1007/BF00209413.PubMedCrossRef Segev H, Reshef A, Clavey V, et al (1995) Premature termination codon at the sterol 27-hydroxylase gene causes cerebrotendinous xanthomatosis in a French family. Hum Genet 95: 238–240. doi:10.​1007/​BF00209413.PubMedCrossRef
Zurück zum Zitat Watts GF, Naoumova RP, Kelly JM, et al (1997) Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 273: E462–E470.PubMed Watts GF, Naoumova RP, Kelly JM, et al (1997) Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 273: E462–E470.PubMed
Zurück zum Zitat Wolthers BG, Walrecht HT, van der Molen JC, et al (1991) Use of determinations of 7-lathosterol (5 alpha-cholest-7-en-3 beta-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J Lipid Res 32: 603–612.PubMed Wolthers BG, Walrecht HT, van der Molen JC, et al (1991) Use of determinations of 7-lathosterol (5 alpha-cholest-7-en-3 beta-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J Lipid Res 32: 603–612.PubMed
Metadaten
Titel
Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX
verfasst von
M. G. M. de Sain-van der Velden
A. Verrips
B. H. C. M. T. Prinsen
M. de Barse
R. Berger
G. Visser
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe Sonderheft 2/2008
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-008-0963-1

Weitere Artikel der Sonderheft 2/2008

Journal of Inherited Metabolic Disease 2/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.